WO2011096642A3 - Pharmaceutical composition for preventing and treating inflammatory diseases - Google Patents

Pharmaceutical composition for preventing and treating inflammatory diseases Download PDF

Info

Publication number
WO2011096642A3
WO2011096642A3 PCT/KR2010/009112 KR2010009112W WO2011096642A3 WO 2011096642 A3 WO2011096642 A3 WO 2011096642A3 KR 2010009112 W KR2010009112 W KR 2010009112W WO 2011096642 A3 WO2011096642 A3 WO 2011096642A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
pharmaceutical composition
inflammatory diseases
treating inflammatory
present
Prior art date
Application number
PCT/KR2010/009112
Other languages
French (fr)
Korean (ko)
Other versions
WO2011096642A2 (en
Inventor
정낙신
이상국
정화진
이혁우
Original Assignee
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이화여자대학교 산학협력단 filed Critical 이화여자대학교 산학협력단
Publication of WO2011096642A2 publication Critical patent/WO2011096642A2/en
Publication of WO2011096642A3 publication Critical patent/WO2011096642A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition for preventing and treating inflammatory diseases, containing 2-[2-chloro-6-(3-iodobenzyl)-furyn-9-yl]-tetrahydro-thiophene-3,4-diol (LJ-1888) or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition according to the present invention has a remarkably low toxicity compared with a known A3 adenosine receptor agonist or antagonist, and is thus useful for preventing and treating inflammatory diseases.
PCT/KR2010/009112 2010-02-02 2010-12-20 Pharmaceutical composition for preventing and treating inflammatory diseases WO2011096642A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0009631 2010-02-02
KR1020100009631A KR101207755B1 (en) 2010-02-02 2010-02-02 Pharmaceutical Composition for Treating Inflammatory Disease

Publications (2)

Publication Number Publication Date
WO2011096642A2 WO2011096642A2 (en) 2011-08-11
WO2011096642A3 true WO2011096642A3 (en) 2011-11-10

Family

ID=44355902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/009112 WO2011096642A2 (en) 2010-02-02 2010-12-20 Pharmaceutical composition for preventing and treating inflammatory diseases

Country Status (2)

Country Link
KR (1) KR101207755B1 (en)
WO (1) WO2011096642A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101323413B1 (en) * 2012-07-26 2013-10-29 이화여자대학교 산학협력단 A pharmaceutical composition for preventing of treating chronic kidney disease comprising (2r,3r,4s)-2-(2-chloro-6-(3-iodobenzylamino)-9h-purin-9-yl)-tetrahydrothiophene-3,4-diol or its derivatives
KR101820909B1 (en) * 2017-07-07 2018-01-23 퓨쳐메디신 주식회사 A pharmaceutical compositions for the prevention and treatment of chronic kidney disease containing adenosine derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008108508A1 (en) * 2007-03-07 2008-09-12 Fm Therapeutics Co., Ltd. Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008108508A1 (en) * 2007-03-07 2008-09-12 Fm Therapeutics Co., Ltd. Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOZAROV, ANDREY ET AL.: "Activation of adenosine low-affinity A3 receptors inhibits the enteric short interplexus neural circuit triggered by histamine", AMERICAN JOURNAL OF PHYSIOLOGY - GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 297, 2009, pages G1147 - G1162 *
MABLEY, JON ET AL.: "The adenosine A3 receptor agonist, N6-(3-iodobenzyl)- adenosine-5'-N-methyluronamide, is protective in two murine models of colitis", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 466, no. 3, 2003, pages 323 - 329 *

Also Published As

Publication number Publication date
WO2011096642A2 (en) 2011-08-11
KR20110090058A (en) 2011-08-10
KR101207755B1 (en) 2012-12-03

Similar Documents

Publication Publication Date Title
WO2006100635A3 (en) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2007150025A3 (en) Purinone derivatives as hm74a agonists
CA2661102C (en) Thiophene derivatives as s1p1/edg1 receptor agonists
MX2010005889A (en) Novel thiophene derivatives.
MY154909A (en) Novel thiophene derivatives
IL192948A0 (en) Novel pyridine derivatives
HK1128471A1 (en) Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
WO2010056022A3 (en) Melanocortin receptor agonists
WO2007150026A3 (en) Purinone derivatives as hm74a agonists
GEP201706774B (en) Heterocyclyl compounds
UA111640C2 (en) DERIVATIVES [1,2,3] TRIAZOLO [4,5-d] PYRIMIDINE AS A cannabinoid receptor agonist 2
WO2011012816A3 (en) Pharmaceutical formulation
WO2010114405A3 (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2010122980A8 (en) NOVEL THYROID HORMONE β RECEPTOR AGONIST
WO2012040048A3 (en) Triazolopyrazinones as p2x7 receptor antagonists
EP3915566A4 (en) Composition for preventing or treating inflammatory bowel disease, containing, as active ingredient, taurodeoxycholic acid or pharmaceutically acceptable salt thereof
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
EP2142549A4 (en) Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
WO2007093365A3 (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008146774A1 (en) Tetrahydroisoquinolin-1-one derivative or salt thereof
ATE496918T1 (en) 5-PHENYL-6-PYRIDINE-4-YL-1,3-DIHYDRO-2H-IMIDAZOÄ4, - BÜPYRIDINE-2-ONE DERIVATIVES SUITABLE AS A2B ADENOSINE RECEPTOR ANTAGONISTS
WO2011135580A3 (en) Pharmaceutical compositions of sirolimus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10845329

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10845329

Country of ref document: EP

Kind code of ref document: A2